Want to see TNDM full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.48Same Quarter Last Year
Moderate Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial momentum—record shipments and sales, meaningful margin expansion, positive cash generation, a strengthened balance sheet, international go‑direct progress, and multiple product and integration milestones (Android Mobi, pregnancy clearance, FreeStyle Libre 3+ and G7 compatibility, Mobi Tubeless filing). Management acknowledged manageable near‑term headwinds from infusion set supplier shortages and the early operational friction of the PayGo pharmacy transition, plus some international timing and one‑time effects. Overall, the positive results, clear roadmap for product launches, and reaffirmed FY guidance outweigh the disclosed challenges.Company Guidance
Record Quarterly Shipments and Sales
Delivered a company first-quarter record with more than 29,000 pump shipments worldwide and $247 million in sales. U.S. shipments exceeded 19,000 (approximately +10% year‑over‑year) and U.S. sales were $161 million (+7% year‑over‑year). Renewals accounted for >50% of shipments; new starts were ~two‑thirds MDI patients.
Margin Expansion and Profitability Progress
Gross margin improved to 55% (nearly +5 percentage points year‑over‑year), the highest first‑quarter gross margin in company history. Adjusted EBITDA was ~1% of sales (benefited from a 32 percentage‑point swing tied to prior‑year IPR&D) and operating margin improved by ~40 percentage points to negative 7%.
Strong Cash Position and Financing
Generated $5 million in free cash flow for the quarter and ended with $570 million in total cash and investments. Completed a convertible debt financing in February with net proceeds of $276 million (0% interest) to strengthen the balance sheet.
Progress on Pharmacy PayGo Transition
Launched PayGo in the pharmacy channel in March and secured ~40% formulary coverage early; pharmacy accounted for ~6% of U.S. sales in Q1. Early adoption was within company assumptions and management reaffirmed conviction in PayGo’s long‑term economics and ability to scale.
International Direct‑to‑Customer Expansion
Launched direct commercial operations in the U.K., Switzerland and Austria; international shipments exceeded 10,000 pumps and international sales were $86 million (+3% year‑over‑year). Direct channel international sales increased to ~11% of international sales (from <5% historically).
Product and Technology Milestones
Expanded Tandem Mobi to Android users in the U.S.; received FDA clearance for Control‑IQ+ in pregnant women (first and only AID cleared for pregnancy in the U.S.); Abbott FreeStyle Libre 3+ integration to begin in select European countries in Q2; Dexcom G7 15‑day compatibility updates planned; commercial rollout of Mobi outside U.S. starting in Q2.
Pipeline Advancement: Mobi Tubeless and Closed‑Loop Pivotal
Planning 510(k) submission for Mobi Tubeless (first Tandem tubeless pump with extended‑wear tech) in Q2 and remain on track to start the pivotal study for Tandem’s fully closed‑loop system later this year.
Reaffirmed 2026 Guidance
Reaffirming full‑year 2026 guidance: worldwide sales $1.065B–$1.085B (U.S. $730M–$745M; international $335M–$340M), expected full‑year gross margin 56%–57% and adjusted EBITDA 5%–6%.
TNDM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TNDM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $18.47 | $15.48 | -16.19% |
Feb 19, 2026 | $18.52 | $24.57 | +32.67% |
Nov 06, 2025 | $13.33 | $16.26 | +21.98% |
Aug 06, 2025 | $14.39 | $11.52 | -19.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Tandem Diabetes Care (TNDM) report earnings?
Tandem Diabetes Care (TNDM) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Tandem Diabetes Care (TNDM) earnings time?
Tandem Diabetes Care (TNDM) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TNDM EPS forecast?
TNDM EPS forecast for the fiscal quarter 2026 (Q2) is -0.33.
